Merus Labs International Company Profile (NASDAQ:MSLI)

About Merus Labs International

Merus Labs International logoMerus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MSLI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.86
  • 50 Day Moving Average: $0.8274
  • 200 Day Moving Average: $0.9309
  • 52-Week Range: $0.70 - $1.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 28.66
  • P/E Growth: 0.0000
  • Market Cap: $100.90M
  • Outstanding Shares: 117,345,000
  • Beta: 1.77
Profitability:
  • Net Margins: -10.36%
  • Return on Equity: -3.94%
  • Return on Assets: -2.20%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 0.77%
  • Quick Ratio: 0.55%
Additional Links:
Companies Related to Merus Labs International:

Analyst Ratings

Consensus Ratings for Merus Labs International (NASDAQ:MSLI) (?)
Ratings Breakdown: 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $4.15 (382.61% upside)

Analysts' Ratings History for Merus Labs International (NASDAQ:MSLI)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017Bloom BurtonReiterated RatingHoldView Rating Details
2/12/2017Canaccord GenuitySet Price TargetBuy$3.00View Rating Details
12/16/2016ScotiabankReiterated RatingSector Perform$1.75 -> $1.25View Rating Details
12/16/2016Paradigm CapitalReiterated RatingHold$1.60 -> $1.00View Rating Details
12/15/2016CIBCReiterated RatingOutperform -> Neutral$2.40 -> $1.50View Rating Details
11/8/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
6/13/2016WedbushReiterated RatingOutperformView Rating Details
6/13/2016GuggenheimReiterated RatingBuyView Rating Details
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30View Rating Details
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60View Rating Details
11/30/2015Royal Bank Of CanadaReiterated RatingSector Outperform$2.90View Rating Details
5/29/2015TD SecuritiesInitiated CoverageBuyView Rating Details
5/26/2015LB SecuritiesReiterated RatingBuy$3.50 -> $3.75View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Merus Labs International (NASDAQ:MSLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q117($0.02)($0.04)$21.35 millionViewListenView Earnings Details
12/18/2014($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
Current Year EPS Consensus Estimate: $-0.0400 EPS
Next Year EPS Consensus Estimate: $0.0300 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.00$0.06$0.03
Q2 20165($0.01)$0.07$0.02
Q3 20163$0.01$0.06$0.04
Q4 20161$0.00$0.00$0.00
Q1 20171($0.01)($0.01)($0.01)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.00$0.00$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Merus Labs International (NASDAQ:MSLI)
DateHeadline
News IconMerus Labs International Inc MSL Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:MSLI)
www.bioportfolio.com - February 17 at 4:45 PM
4-traders.com logoMerus Labs International : Reports Fiscal Q1 2017 Results (NASDAQ:MSLI)
www.4-traders.com - February 14 at 8:44 PM
finance.yahoo.com logoMerus Labs Reports Fiscal Q1 2017 Results (NASDAQ:MSLI)
ca.finance.yahoo.com - February 14 at 8:44 PM
seekingalpha.com logoMerus Labs International's (MSLI) CEO Barry Fishman on Q1 2017 Results - Earnings Call Transcript (NASDAQ:MSLI)
seekingalpha.com - February 14 at 8:44 PM
sg.finance.yahoo.com logoMerus Labs reports 1Q loss (NASDAQ:MSLI)
sg.finance.yahoo.com - February 14 at 8:44 PM
reuters.com logoBRIEF-BEUTEL, GOODMAN & CO REPORTS 14.12 PCT PASSIVE STAKE IN MERUS LABS (NASDAQ:MSLI)
in.reuters.com - January 23 at 7:00 PM
finance.yahoo.com logoWhat Makes Merus Labs (MSLI) a Strong Sell? (NASDAQ:MSLI)
finance.yahoo.com - January 9 at 7:23 PM
capitalcube.com logoMerus Labs International, Inc. :MSLI-US: Earnings Analysis: 2016 By the Numbers : December 21, 2016 (NASDAQ:MSLI)
www.capitalcube.com - December 21 at 10:24 AM
marketexclusive.com logoAnalyst Activity – Scotiabank Reiterates Sector Perform on Merus Labs International (NASDAQ:MSLI) (NASDAQ:MSLI)
marketexclusive.com - December 17 at 7:03 PM
seekingalpha.com logoMerus Labs slumps 15% on fiscal year-end and Q4 results; modest growth in non-GAAP earnings expected (NASDAQ:MSLI)
seekingalpha.com - December 15 at 12:22 AM
finance.yahoo.com logoMerus Labs Reports Fiscal Q4 and 2016 Results (NASDAQ:MSLI)
finance.yahoo.com - December 14 at 7:21 PM
News IconMerus Labs International, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 (NASDAQ:MSLI)
www.bioportfolio.com - December 4 at 5:50 PM
publicnow.com logoMerus Labs Receives NASDAQ Notice Regarding Minimum Bid Price Requirements (NASDAQ:MSLI)
www.publicnow.com - November 18 at 5:52 PM
News IconAurora Cannabis Adds Pharmaceutical Industry Veteran to Board of Directors (NASDAQ:MSLI)
www.newcannabisventures.com - October 13 at 9:49 AM
finance.yahoo.com logoBarry Fishman Joins Aurora Board as Independent Director (NASDAQ:MSLI)
finance.yahoo.com - October 12 at 11:35 AM
publicnow.com logoMerus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage (NASDAQ:MSLI)
www.publicnow.com - October 3 at 10:50 AM
News IconMerus Labs (MSLI) Tanks on Weak Q3 Financial Results (NASDAQ:MSLI)
www.economiccalendar.com - August 15 at 6:31 PM
sg.finance.yahoo.com logoMerus Labs reports 3Q loss (NASDAQ:MSLI)
sg.finance.yahoo.com - August 15 at 6:31 PM
4-traders.com logoMerus Labs International : Reports Fiscal Q3 2016 Results (NASDAQ:MSLI)
www.4-traders.com - August 15 at 8:30 AM
finance.yahoo.com logoMerus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release (NASDAQ:MSLI)
finance.yahoo.com - August 10 at 6:43 PM
publicnow.com logoMerus Labs Appoints Two Senior Executives (NASDAQ:MSLI)
www.publicnow.com - July 4 at 8:51 AM
finance.yahoo.com logoMerus Announces Reduced Leverage and Provides Business Update (NASDAQ:MSLI)
finance.yahoo.com - July 4 at 7:00 AM
finance.yahoo.com logoMerus Labs Appoints Two New Senior Executives (NASDAQ:MSLI)
finance.yahoo.com - June 30 at 4:00 PM
investornewswire.com logoMerus Labs International Inc. (NASDAQ:MSLI) Reports Yearly Sales Estimate At $93.125 - Investor Newswire (NASDAQ:MSLI)
www.investornewswire.com - May 26 at 11:49 AM
finance.yahoo.com logoMerus Labs International Inc. Announces Deemed Exercise of Special Warrants (NASDAQ:MSLI)
finance.yahoo.com - May 18 at 4:24 PM
sg.finance.yahoo.com logoMerus Labs reports 2Q loss (NASDAQ:MSLI)
sg.finance.yahoo.com - May 11 at 5:56 PM
finance.yahoo.com logoMerus Labs Reports Fiscal Q2 2016 Results (NASDAQ:MSLI)
finance.yahoo.com - May 11 at 4:00 PM
publicnow.com logoMerus Announces Re-Election of Directors (NASDAQ:MSLI)
www.publicnow.com - April 4 at 12:00 PM
publicnow.com logoMarch 7, 2016 Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi (NASDAQ:MSLI)
www.publicnow.com - April 4 at 12:00 PM
streetinsider.com logoMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal (NASDAQ:MSLI)
www.streetinsider.com - February 2 at 2:12 PM
finance.yahoo.com logo2:55 pm Merus Labs to acquire UCB's rights to Elantan, Isoket and Deponit in Europe and select other markets for EUR92 mln; updates FY16 EBITDA guidance (shares halted) (NASDAQ:MSLI)
finance.yahoo.com - February 1 at 2:55 PM
finance.yahoo.com logoMERUS LABS INTERNATIONAL INC. Financials (NASDAQ:MSLI)
finance.yahoo.com - January 5 at 1:04 PM
finance.yahoo.com logoMerus Labs Announces Filing of Preliminary Base Shelf Prospectus (NASDAQ:MSLI)
finance.yahoo.com - July 10 at 7:00 AM
finance.yahoo.com logoMerus Labs Provides an Update on German Reimbursement Review (NASDAQ:MSLI)
finance.yahoo.com - June 3 at 4:00 PM

Social

What is Merus Labs International's stock symbol?

Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."

Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?

8 brokers have issued twelve-month price objectives for Merus Labs International's shares. Their forecasts range from $1.00 to $14.00. On average, they anticipate Merus Labs International's stock price to reach $4.15 in the next year.

What are analysts saying about Merus Labs International stock?

Here are some recent quotes from research analysts about Merus Labs International stock:

  • According to Zacks Investment Research, "Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company's products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada. " (2/15/2017)

  • Canaccord Genuity analysts commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic diseases and infections. While we acknowledge that the near-term focus of investors may be how the primary endpoint of reducing the relative risk of infection recurrence in the SER-109 Phase II ECOSPOR clinical study in recurrent Clostridium difficile infection (CDI) was not achieved, we think the stock sell-off since July 29 is overdone. The development of MCRB’s other clinical-stage assets are partnered with Swiss-based Nestle, which has agreed to fund up to one-third of development costs, according to a $1.9B agreement signed in January 2016. MCRB has also signed four other collaborations, which we think represent nascent upside potential in the stock." (8/12/2016)

Who owns Merus Labs International stock?

Merus Labs International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Guardian Capital LP (1.01%) and I.G. Investment Management LTD. (0.12%).

Who sold Merus Labs International stock? Who is selling Merus Labs International stock?

Merus Labs International's stock was sold by a variety of institutional investors in the last quarter, including I.G. Investment Management LTD..

How do I buy Merus Labs International stock?

Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merus Labs International stock cost?

One share of Merus Labs International stock can currently be purchased for approximately $0.86.

Merus Labs International (NASDAQ:MSLI) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Merus Labs International (NASDAQ:MSLI)

Earnings History Chart

Earnings by Quarter for Merus Labs International (NASDAQ:MSLI)

Dividend History Chart

Dividend Payments by Quarter for Merus Labs International (NASDAQ:MSLI)

Last Updated on 2/23/2017 by MarketBeat.com Staff